In her book Bottle of lies: Ranbaxy and the dark side of Indian pharma, author Katherine Eban, clearly and convincingly sets out a case against the corruption that has infiltrated the generic drug industry, and Ranbaxy Ltd. in particular. The focus is on India, though many of the same arguments probably could be used for China, another major producer of generic drugs. Some elements in India, including government and the generic drug industry have struck back, accusing the author of maligning Indian pharma, and in the process, helping multinationals. Rather than “shooting the messenger”’ it might be best to address the issues that have been raised.